You are viewing the site in preview mode

Skip to content

Advertisement

  • Research
  • Open Access

Evaluation of multiple institutions’ models for knowledge-based planning of volumetric modulated arc therapy (VMAT) for prostate cancer

  • 1,
  • 2,
  • 3,
  • 4,
  • 5 and
  • 6Email author
Radiation Oncology201813:46

https://doi.org/10.1186/s13014-018-0994-1

  • Received: 27 December 2017
  • Accepted: 8 March 2018
  • Published:

Abstract

Background

The aim of this study was to evaluate the performance of a commercial knowledge-based planning system, in volumetric modulated arc therapy for prostate cancer at multiple radiation therapy departments.

Methods

In each institute, > 20 cases were assessed. For the knowledge-based planning, the estimated dose (ED) based on geometric and dosimetric information of plans was generated in the model. Lower and upper limits of estimated dose were saved as dose volume histograms for each organ at risk. To verify whether the models performed correctly, KBP was compared with manual optimization planning in two cases. The relationships between the EDs in the models and the ratio of the OAR volumes overlapping volume with PTV to the whole organ volume (Voverlap/Vwhole) were investigated.

Results

There were no significant dosimetric differences in OARs and PTV between manual optimization planning and knowledge-based planning. In knowledge-based planning, the difference in the volume ratio of receiving 90% and 50% of the prescribed dose (V90 and V50) between institutes were more than 5.0% and 10.0%, respectively. The calculated doses with knowledge-based planning were between the upper and lower limits of ED or slightly under the lower limit of ED. The relationships between the lower limit of ED and Voverlap/Vwhole were different among the models. In the V90 and V50 for the rectum, the maximum differences between the lower limit of ED among institutes were 8.2% and 53.5% when Voverlap/Vwhole for the rectum was 10%. In the V90 and V50 for the bladder, the maximum differences of the lower limit of ED among institutes were 15.1% and 33.1% when Voverlap/Vwhole for the bladder was 10%.

Conclusion

Organs’ upper and lower limits of ED in the models correlated closely with the Voverlap/Vwhole. It is important to determine whether the models in KBP match a different institute’s plan design before the models can be shared.

Keywords

  • Knowledge-based planning
  • Inverse planning
  • Prostate cancer
  • Quality assurance for planning
  • RapidPlan

Background

The plan quality for intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT), which are created by inverse planning, depends on the planner’s or institution’s experience and skills [13]. Institutional experience substantially influences survival in locally advanced head and neck cancer [4]. Some studies have suggested methods to verify the quality of plans created by inverse planning [57].

For quality assurance of an inverse planning algorithm, Moore et al. [5] reported that predicting the dose to an organ at risk (OAR) from the volume of the OAR within the planning target volume (PTV) was useful to reduce variations in planning quality. Recently, a new assistance tool for inverse planning, RapidPlan (Varian Medical Systems, Palo Alto CA, USA), which performs knowledge-based planning (KBP), was developed and released for clinical use. Details of the system have been described in a previous study [8]. Some studies have suggested that the performance of KBP be compared with manually-optimized plans for clinical use. They mentioned that KBP is superior to manual planning in reducing OAR dose [912].

The KBP system has the advantage that its model is shared by multiple institutions. Sharing models is considered to be a good method for reducing variability in planning quality among multiple institutions. There has been no report that KBP with the models in multiple institutions was employed for the same CT data. The aim of this study was to evaluate the performance of KBP models in multiple institutions to optimize the model.

Methods

Institutes and plan design

In this study, five institutes (A–E) were enrolled. These institutes treated patients with T1–T2c prostate cancer using VMAT. Table 1 shows the definition of gross tumor volume (GTV), margins to define the clinical target volume (CTV) and PTV in each direction. In each institution, the dose constraints are shown in Table 2. The five institutes had different plan designs.
Table 1

The definition of gross tumor volume (GTV), margins to define the clinical target volume (CTV) and PTV in each direction

Institute

Gross tumor volume (GTV)

GTV to CTV margin [mm]

CTV to PTV margin [mm]

A

P

S

I

L

R

A

P

S

I

L

R

A

Prostate and proximal 20 mm of SV

0

3

3

0

3

3

4

4

4

4

4

4

B

Prostate and proximal 15 mm of SV

0

0

0

0

0

0

8

5

8

8

8

8

C

Prostate and proximal 10 mm of SV

0

0

0

0

0

0

6

4

6

6

6

6

D

Prostate

3

3

3

3

3

3

3

3

3

3

3

3

E

Prostate and the half of SV

0

0

0

0

0

0

8

6

8

8

8

8

Abbreviations: GTV the gross tumor volume, CTV the clinical target volume, PTV the planning target volume, SV the seminal vesicle, A the anterior direction, P the posterior direction, S the superior direction, I inferior direction, L the left direction, R the right direction

Table 2

Dose constraints for treatment of prostate cancer using volumetric-modulated arc therapy in each institution

Institute

Organ

Target

Rectum

Bladder

CTV

PTV

A

Ractal wall

Bladder wall

CTV

PTV

V78 (Gy) ≤ 0.1 cm3

V70 (Gy) ≤ 35%

Dmin ≥100%

D50 = 100%

V70 (Gy) ≤ 25%

V40 (Gy) ≤ 60%

  

V60 (Gy) ≤ 35%

   

V40 (Gy) ≤ 60%

   

B

Ractal wall

Bladder wall

CTV

PTV sub. Rectum

V78 (Gy) < 1%

V70 (Gy) < 35%

 

Dmean < 103%

V70 (Gy) < 20%

V40 (Gy) < 60%

 

Dmin > 99%

V60 (Gy) < 30%

  

Dmax < 110%

V40 (Gy) < 60%

  

D95 = 100%

C

Rectum

Bladder

CTV

PTV

V70 (Gy) ≤ 5%

V80 (Gy) ≤ 5%

D98 ≥ 98%

Dmean = 100%

V65 (Gy) ≤ 10%

V75 (Gy) ≤ 15%

D2 ≤ 105%

D95 ≥ 95%

V60 (Gy) ≤ 20%

V70 (Gy) ≤ 25%

 

V90 ≥ 98%

V40 (Gy) ≤ 40%

V60 (Gy) ≤ 40%

 

D2 ≤ 105%

D

Rectum sub. PTV

Bladder sub. PTV

CTV

PTV sub. (Rectum and bladder)

D50 ≤ 69.7%

D5 ≤ 78.9%

D95 = 100%

68.4% ≤ D5 ≤ 71.1%

D5 ≤ 78.9%

D50 ≤ 72.4%

88.2% ≤ D5 ≤ 92.1%

65.8% ≤ D50 ≤ 71.1%

  

85.5% ≤ D50 ≤ 88.2

64.5% ≤ D95 ≤ 68.4%

  

81.6% ≤ D95 ≤ 85.5

 

E

Ractal wall

Bladder wall

CTV

PTV

V78 (Gy) ≤ 1%

V70 (Gy) ≤ 35%

 

Dmean = 100%

V70 (Gy) ≤ 20%

V40 (Gy) ≤ 60%

 

D95 ≥ 95%

V60 (Gy) ≤ 35%

  

V90 ≥ 98%

V40 (Gy) ≤ 60%

  

Dmax ≤110%

Abbreviations: CTV the clinical target volume, PTV the planning target volume, Dmean mean dose, Dmin minimum dose, Dmax maximum dose, V80, V78, V70, V65, V60, and V40 the OAR volume ratio that receives a dose exceeding 80 Gy, 78 Gy, 70 Gy, 65 Gy, 60 Gy, and 40 Gy, V90 the volume ratio receiving 90% of the prescribed dose, D95, D50, D5, and D2 the dose received by at least 95%, 50%, 5.0%, and 2.0% of the volume

The model for KBP and exporting the estimated dose

In each institute, the model for KBP was created using the VMAT plans for clinical use at each institute before April 2017. The number of registered cases in institute A, institute B, institute C, institute D, and institute E were 123, 53, 20, 60, and 100, respectively.

Users performed three main steps to create models for KBP. In the first step, dose volume histogram (DVH) estimation model configuration, > 20 plans that had been used in clinical settings were registered. The next step was the extraction phase. In each OAR of registered plans, dosimetric and geometric information was imported in the model. The last step was the training step, based on the information from the extraction phase. In this step, in each OAR of registered plans new DVH curves were generated. Upper and lower limits of the estimated doses (ED) were obtained. These dose limits were saved in the form of DVH in the model. To attain the ideal dose distribution, the parameters, except line objects shown in Table 3, were set in some institutes.
Table 3

Objectives except line objects in models

 

Organ

Target

Objective type

Volume

Dose

gEUD

Priority

Objective type

Volume

Dose

Priority

A

Rectum

CTV

Upper

0

100%

 

58

Upper

0

104%

100

Bladder

Lower

100

100%

63

Upper

0

100%

 

58

PTV

   
     

Upper

0

104%

100

     

Lower

100

90%

63

B

Rectum

CTV

Upper

0

98%

 

45–50

    

Bladder

PTV

     

Upper

0

102%

120

     

Lower

100%

100%

120

C

Rectum

CTV

Upper

0

100%

 

generate

    

Upper gEUD

 

69.2%

9

generate

PTV

Bladder

Upper

0

100%

115

     

Lower

100%

93%

generate

     

Lower

97%

96%

generate

     

Lower

95.50%

98%

generate

     

Lower

90%

100%

generate

D

Rectum

CTV

Upper

0

78.9%

 

generate

Upper

0

102.6%

generate

Bladder

Lower

95%

100%

generate

Upper

0

81.6%

 

generate

Lower

100%

97.4

generate

     

PTV

     

Upper

0

97.4%

generate

     

Lower

0

94.7%

generate

E

Rectum

CTV

Upper

0

99.0%

 

generate

Lower

100.0%

99.0%

generate

Upper gEUD

 

77.0%

10.0

generate

PTV

Bladder

Upper

0.0%

103.0%

generate

     

Lower

100.0%

90.0%

generate

     

Lower

97.0%

97.0%

generate

Abbreviations: CTV the clinical target volume, PTV the planning target volume, gEUD generalized equivalent uniform dose

These data were read from an .xml file exported to the website of Model Analytics (https://ModelAnalytics.varian.com). The file also contained basic information on the model, such as original and estimated DVH data and OAR volume, and the ratio of an OAR’s volume overlapping with PTV to the whole organ volume (Voverlap/Vwhole). To evaluate the performance in reducing the dose to rectum and bladder in each model, the original DVH, and upper and lower limits of ED, were extracted from the file.

Calculation of dose distributions with manual optimization and KBP

To investigate whether KBP was performed correctly, two sets of CT data and structures of patients at institute B were anonymized and delivered to other institutes. Written informed consent was obtained from all patients, and the Institutional Ethics Committee approved this study (Kindai University review board number: 29–133). The thickness of the CT sections was 2.5 mm and the field of view was 50 cm. The target and OARs were contoured by a physician according to the protocol of institute B. The bladder in one case (case I) had a volume of 83.8 cm3, in another case (case II), bladder volume of 181.8 cm3. Voverlap/Vwhole of the rectum and bladder were 9.8% and 11.1% in case I and 5.9% and 5.9% in case II, respectively.

At each institute, the planners who participated in this study had experience with inverse planning for IMRT or VMAT with the Eclipse (Varian Medical Systems, Palo Alto CA, USA) treatment planning system (TPS). They attended a special lecture (RapidPlan Clinical Advisory Board) on Rapidplan held by the manufacturer in Tokyo in June 2017. In KBP using Rapidplan, single optimization was performed. Next, in the manual optimization planning, the optimization was repeated until it achieved the institutional ideal dose distribution. In manual optimization, the generalized equivalent uniform dose (gEUD) was not used in all institutes. In KBP and manual optimization planning, the same calculation parameters and beam parameters were used. The photon optimization was used with 2.5 mm grid size. The calculation algorithm was Anisotropic Analytical Algorithm ver. 13.0 (Varian Medical Systems, Palo Alto CA, USA).

Results

Original PTV and OAR’s volume and DVH data registered for each model

The mean ± SD of the PTV registered for each model were 91.4 ± 26.0 cm3, 99.5 ± 35.6 cm3, 82.0 ± 16.9 cm3, 136 ± 35.1 cm3, and 95.3 ± 24.5 cm3 for institutions A, B, C, D, and E, respectively. In the original OAR’s volume registered in each model, the mean ± SD of the rectal volume were 50.1 ± 13.7 cm3, 59.7 ± 24.9 cm3, 50.3 ± 14.2 cm3, 54.3 ± 21.9 cm3, and 45.2 ± 14.1 cm3 for institutions A, B, C, D, and E, respectively. The mean ± SD of the bladder volume were 151.3 ± 69.2 cm3, 165.1 ± 98.4 cm3, 179.5 ± 63.4 cm3, 80.7 ± 44.9 cm3, and 172.8 ± 101.7 cm3 for institutions A, B, C, D, and E, respectively. The mean ± SD of the rectal volume overlapping with PTV were 5.0 ± 1.4 cm3, 3.2 ± 1.4 cm3, 2.9 ± 1.2 cm3, 3.6 ± 1.3 cm3, and 4.6 ± 1.8 cm3 for institutions A, B, C, D, and E, respectively. The mean ± SD of the bladder volume overlapping with PTV were 8.3 ± 3.3 cm3, 12.5 ± 7.0 cm3, 8.9 ± 3.9 cm3, 5.9 ± 2.1 cm3, and 12.6 ± 4.4 cm3 for institutions A, B, C, D, and E, respectively. The mean ± SD of the Voverlap/Vwhole for the rectum were 10.4% ± 3.0%, 6.0% ± 2.7%, 5.8% ± 2.2%, 7.2% ± 2.8%, and 10.5% ± 3.8% for institutions A, B, C, D, and E, respectively. The mean ± SD of the Voverlap/Vwhole for the bladder were 6.4% ± 3.1%, 8.7% ± 3.9%, 5.1% ± 2.3%, 9.2 ± 10.2%, and 9.0% ± 4.4% for institutions A, B, C, D, and E, respectively.

In the original DVH data registered for each model, the mean ± SD of the rectal volume ratio receiving 90% of the prescribed dose (V90) were 11.2% ± 3.2%, 11.3% ± 3.3%, 5.7% ± 2.5%, 1.4% ± 1.3%, and 15.4% ± 3.6% at institutions A, B, C, D, and E, respectively. The mean ± SD of the rectal volume ratio receiving 50% of the prescribed dose (V50) were 37.5% ± 7.0%, 37.8% ± 9.1%, 25.2% ± 6.4%, 69.2% ± 12.6%, and 45.3% ± 6.5% at institutions A, B, C, D, and E, respectively. The mean ± SD of V90 of the bladder were 6.4% ± 3.1%, 16.4% ± 6.0%, 9.1% ± 3.6%, 5.8% ± 4.0%, and 10.9% ± 5.0% at institutions A, B, C, D, and E, respectively. The mean ± SD of V50 of the bladder were 27.9% ± 11.4%, 42.0% ± 14.9%, 24.5% ± 8.7%, 62.6% ± 20.1%, and 34.3% ± 14.3% at institutions A, B, C, D, and E, respectively. The box plots of the rectal and bladder dose are shown in Fig. 1. The median of each rectal dose for institute E were the highest among the sites. Those for institute C were the smallest. The median of each bladder dose for institute B was the highest.
Fig. 1
Fig. 1

Box plots for rectal and bladder doses registered for each model at each institute. (a) The rectal volume receiving 90% of the dose (V90) in original dose volume histogram (DVH) curves for each model. (b) The rectal volume receiving 50% of the dose (V50) in original DVH curves for each model. (c) V90 of the bladder in original DVH curves for each model. (d) V50 of the bladder in original DVH curves for each model

Manual optimization planning vs. KBP

In the rectal and bladder doses calculated by KBP and manual optimization planning, V90 and V50 are shown in Fig. 2 (a), (b), (e), and (f). In the V90 of the rectum, the mean ± SD of difference between KBP and manual optimization planning was 0.4% ± 1.6% and − 0.1% ± 1.5% in cases I and II, respectively. A negative value implies that dosimetric values for KBP were higher than those for manual optimization planning. In the V50 of the rectum, the mean ± SD of difference between KBP and manual optimization planning was 2.2% ± 6.9% and 2.6% ± 8.0% in cases I and II, respectively. For the V90 of the bladder, the mean ± SD of difference between KBP and manual optimization planning was 1.3% ± 2.0% and 1.0% ± 0.9% in cases I and II, respectively. For the V50 of the bladder, the mean ± SD of differences between KBP and manual optimization planning was 4.8% ± 5.0% and 3.6% ± 0.9% in cases I and II, respectively.
Fig. 2
Fig. 2

Comparison between knowledge-based planning (KBP) and manual optimization planning in rectal and bladder doses. (a) and (e) are the volume receiving 90% of the dose (V90) of rectum and bladder. (b) and (f) are the volume receiving 50% of the dose (V50) of rectum and bladder. (c) and (g) are the dose received by at least 95% of the volume (D95) of the rectum and bladder, and (d) and (h) are the dose received by at least 2% of the volume (D2) for the rectum and bladder. Circles in each graph are dosimetric parameters of case I and squares are case II. The colors of the circles, squares, and lines represent institutes. (Blue: a, Orange: b, Gray: c, Green: d, and Yellow: e)

The dose received by at least 95% of the volume (D95) for the OARs is shown in Fig. 2 (c) and (g). For the D95 of the rectum, the mean ± SD of differences between KBP and manual optimization planning was 0.5% ± 1.9% and 0.1% ± 2.7% in cases I and II. For the D95 of the bladder, the mean ± SD of differences between KBP and manual optimization planning was 1.4% ± 2.0% and 1.2% ± 2.0% in cases I and II. There were no significant differences in each dosimetric parameter between the cases.

The dose received by at least 2% of the volume (D2) for the organs is shown in Fig. 2 (d) and (h). In the D2 for the rectum, the mean ± SD of the difference between KBP and manual optimization planning were − 0.5% ± 0.8% and − 0.9% ± 1.8% in cases I and II. In the D2 for the bladder, the mean ± SD of difference between KBP and manual optimization planning were − 0.1% ± 0.8% and − 0.2% ± 1.3% in cases I and II. There were no significant differences in each dosimetric parameter between the cases.

Various dosimetric values were calculated by KBP among institutes even if they used the same dosimetric parameters. Among institutions, the maximum differences in V90 for the rectum were 6.7% and 6.7%, V50 for the rectum were 39.0% and 41.9%, V90 of the bladder were 18.2% and 9.9%, and V50 of the bladder were 12.5% and 6.7% in cases I and II, respectively. These results suggested that each institutional KBP was useful in that particular institute regardless of the number of registered plans in the model, but the performance varied widely among the institutes.

The relationship estimated dose and overlap volumes

Figure 3 shows the relationships between the upper limit and lower limit of ED and Voverlap/Vwhole for the rectum and the bladder, in institutes A and B. Dotted lines are quadratic regression curves between EDs and the Voverlap/Vwhole. The black dots are dosimetric values calculated by KBP in cases I and II. Black dots were compiled with regression curves for each organ. The dosimetric values that were calculated by KBP were between curves of the upper and lower limits of ED or slightly lower than the curve of the lower limit of ED. In each organ, coefficients of determination (R2) of each dosimetric value and Voverlap/Vwhole for the rectum and the bladder are shown in Table 4. The R2 values of V90 were greater than those for V50, except at institution B for the rectum. In the bladder, the R2 of V90 were more than those for V50 at all institutions.
Fig. 3
Fig. 3

Relationship between estimated dose (ED) and ratio of an OAR’s volume overlapping with PTV to the whole organ volume (Voverlap/Vwhole) for the rectum and bladder in institute a (a), (b), (e), (f) and b (c), (d), (g), (h). The horizontal axis is the Voverlap/Vwhole for the rectum (a, b, c, d) and Voverlap/Vwhole for the bladder (e, f, g, h). The vertical axis is the V90 to rectum (a, c) or bladder (e, g). The vertical axis is the V50 for the rectum (b, d) or bladder (f, h). Yellow dots represent the upper limit of ED and blue dots, the lower limit of ED. Red dotted lines with coefficients of determination (R2) are quadratic regression curves between each organ dose and Voverlap/Vwhole for organs. Black dots are calculated doses with knowledge-based planning (KBP) in cases I and II

Table 4

Coefficients of determination (R2) of between each dosimetric value (V90 and V50) and ratio of an OAR’s volume overlapping with PTV to the whole organ volume (Voverlap/Vwhole).vb

Institutions

Organs

Dosimetric Parameters

Coefficients of determination (R2) in the quadratic regression curves

DVH for registered plans

Upper limit of ED

Lower limit of ED

A

Rectum

V90

0.601

0.996

0.994

V50

0.488

0.864

0.877

Bladder

V90

0.865

0.998

0.997

V50

0.781

0.852

0.903

B

Rectum

V90

0.254

0.133

0.011

V50

0.293

0.158

0.138

Bladder

V90

0.845

0.935

0.911

V50

0.695

0.679

0.698

C

Rectum

V90

0.666

0.967

0.961

V50

0.592

0.826

0.839

Bladder

V90

0.885

0.931

0.962

V50

0.620

0.594

0.649

D

Rectum

V90

0.529

0.997

0.995

V50

0.485

0.494

0.519

Bladder

V90

0.987

0.999

0.999

V50

0.515

0.544

0.578

E

Rectum

V90

0.626

0.944

0.946

V50

0.169

0.334

0.435

Bladder

V90

0.971

0.994

0.994

V50

0.804

0.849

0.866

Abbreviations: DVH dose volume histogram, ED estimated dose, V90 the volume ratio of receiving 90% of the prescribed dose, V50 the volume ratio of receiving 50% of the prescribed dose

Estimated vs. calculated dose

Quadratic regression curves between lower limit of ED and Voverlap/Vwhole for the rectum with the formulas for all institutes are shown in Fig. 4 (a), (b). In the V90 of the rectum (Fig. 4 [a]), four institutes except institute B had regression curves that tended to increase with increasing Voverlap/Vwhole for the rectum. In institute B, the regression curve was almost horizontal. The V90 dose in institute E was the highest of all Voverlap/Vwhole for the rectum. When Voverlap/Vwhole for the rectum was about 10%, the difference in the lower limits of ED between institutions D and E was > 8%. In the V50 for the rectum (Fig. 4 [b]), Institute D had the highest lower limit of ED in all Voverlap/Vwhole for the rectum. When the Voverlap/Vwhole for the rectum was 10%, the difference in lower limit of ED between institutes C and D was > 50%.
Fig. 4
Fig. 4

Quadratic regressions curves between lower limit of estimate dose (ED) and ratio of an OAR’s volume overlapping with PTV to the whole organ volume (Voverlap/Vwhole) for the rectum and bladder with the formulas for all institutes. The horizontal axis is the Voverlap/Vwhole for the rectum (a, b) and bladder (c, d). The vertical axis is the volume receiving 90% of the prescribed dose (V90) to the rectum (a) and bladder (c). The vertical axis is the volume receiving 50% of the prescribed dose (V50) for the rectum (b) and bladder (d). The colors of the dotted lines represent institutes. (Blue: a, Orange: b, Gray: c, Green: d, and Yellow: e)

In the V90 and V50 for the bladder (Fig. 4 [c], [d]), the lower limit of ED curves for all institutes tended to show increases with increasing Voverlap/Vwhole for the bladder. In the V90 for the bladder (Fig. 4 [c]), when Voverlap/Vwhole for the bladder was 10%, the slopes of lower limits of ED for institutes B and C were steeper than those for institutions A, D, and E. In the V50 for the bladder (Fig. 4 [d]), Voverlap/Vwhole for the bladder was approximately 10%, the lower limits of ED were almost the same for institutes A, C, and E. The slope of the curves varied according to facilities. In among institutions, the maximum differences for lower limit of ED of V90 for the rectum were 8.2% and 5.7%, V50 for the rectum 53.5% and 45.0%, V90 for the bladder 15.1% and 9.4%, V50 to the bladder 33.1% and 26.0% when overlap volume with PTV was 10.0% and 6.0%, respectively.

Discussion

In this study, five institutes used KBP for two cases each and the performance of the KBP models was compared among institutions. Some reports have evaluated the utility of KBP with one model [912]. This study uncovered that KBP performed effectively in five institutes, creating plans for clinical use. Each institute had its own plan design. KBP performed correctly regardless of the plan designs. This result suggests that the KBP models produced similar dose distributions as those of the model’s institutions with KBP. Additionally, in registered numbers of plans in each model, only 20 cases might be enough if there are large variations in the registered cases.

Kubo et al. [12] described that the dose coverage to the PTV was slightly inferior in KBP plans compared with manual optimization planning, as can be seen in values for D95 and D2. They used predicted priority values for PTV to confirm KBP predicted accuracy; these values might be underestimated to achieve the dose constraint objectives. In this study, the dose to the PTV was slightly inferior in KBP plans compared with manual optimization planning in some institutes, although there was no significant difference in D95 for the rectal and bladder volumes within the PTV. The first priority was reducing OAR dose for the KBP.

Schubert et al. have proven that it is possible to share models among different institutes in a cooperative framework [13]. Institutes in the report had the same plan design. In this study, in the KBP for multiple institutions, the maximum dosimetric differences for the V90 and V50 calculated with KBP among institutions were > 6.0% in cases I and II in both bladder and rectum. These results suggest that values calculated with KBP were influenced by plans registered in the model. Therefore, it depends on plan designs were matching between institutions whether the models made in other institutions can be shared.

Moore et al. found that that an OAR’s mean dose strongly correlated with the rectal and bladder volumes within the PTV [5]. In inverse planning, the understanding of geometric displacements of PTV and OARs led to predicting OAR dose and reducing the planner’s variations [57]. In this study, it was suggested that V90 and V50 had also strong correlation with the rectal and bladder volumes within the PTV in almost institutes. It was found that the correlation tendencies were different among institutes. To optimize the model for a case, it was acceptable to verify the relationship between OARs dose and the rectal and bladder volumes within the PTV.

Tol et al. [7] found that there were strong linear correlations (R2 = 0.94–0.99) between estimated and achieved mean doses in KBP. They derived the estimated mean dose from KBP models. The ED of the model was important for understanding the performance of KBP. In this study, EDs for V50 and V90 were compared between institutes. To reduce the volume, such as V50 and V90 for the OARs, leads to prevent radiation toxicity for the rectum and bladder. Peeters et al. argued that both intermediate and high doses to the anorectal wall volume should be considered to evaluate the risk of late GI toxicity [14]. Harsolia et al. found the volume of the bladder wall receiving ≥30 and ≥ 80 Gy predicted grade ≥ 2 late toxicity and grade 3 late toxicity [15]. In this study, it was indicated that the calculated OAR dose with KBP depended on registered plans in the model and correlated with OARs volumes in the PTV strongly. Thus, predicting OAR dose from the Voverlap/Vwhole for the rectum and bladder will be required to select the optimal model among several models.

In the relationships between OAR dose and the rectal and bladder volumes within the PTV, R2 values of V90 were higher than those of V50, except the rectum in institute B, because the OAR volume in the PTV affects the high dose region in the DVH curve [8]. In institute B, R2 values of the rectum were lower than those of other institutes. V90 for the rectum registered in the model was weak correlation with Voverlap/Vwhole although there were strong correlations in other institutions. In plan designs at institutions except institute B, V90 for the rectum depended on the rectal volume within the PTV. The correlation values between the R2 for EDs and dose for original DVH in the model were strong, 0.793 and 0.783 as Table 4. This result was showed the plan designs of plans registered in the models affected the relationships between ED and Voverlap/Vwhole.

Conclusions

It has been suggested that KBP performs correctly regardless of institutional plan design. KBP was able to reproduce dose distributions based on the experience of institutions. There was very wide variation in the organ dose calculated with KBP among sites. To share models for KBP, it will be necessary to determine whether the registered DVH curves in the models match the plan design. The models for the KBP were characterized with the ratio of OAR’s volume overlapping with the PTV to the whole organ volume.

Abbreviations

CTV: 

Clinical target volume

D2: 

Dose received by at least 2% of the volume

D95: 

Dose received by at least 95% of the volume

DVH: 

Dose volume histogram

ED: 

Estimated doses

gEUD: 

Generalized equivalent uniform dose

GTV: 

Gross tumor volume

IMRT: 

Intensity-modulated radiotherapy

KBP: 

Knowledge-based planning

OAR: 

Organ at risk

PTV: 

Planning target volume

TPS: 

Treatment planning system

V50: 

Volume receiving 50% of the prescribed dose

V90: 

Volume receiving 90% of the prescribed dose

VMAT: 

Volumetric-modulated arc therapy

Voverlap/Vwhole

Ratio of an OAR’s volume overlapping with PTV to the whole organ volume

Declarations

Acknowledgements

We thank Edanz Group (https://www.edanzediting.com) for editing a draft of this manuscript.

Funding

This study was supported by JSPS KAKENHI Grant (17 K15817).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

Concept and design: UY, FJ, KT, AY, MH. Treatment planning: UY, FJ, KT, AY, NK, MH. Data analysis: UY, FJ, KT, AY, MH. Manuscript preparation: UY, MH. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by each institutional ethical review committee with written informed consent provided by the patients.

Consent for publication

The institutional consent form was obtained from the patients.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Radiation Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka 537-8567, Japan
(2)
Divisin of Radiology, Department of Medical Technology, Kyushu University Hospital, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
(3)
Department of Radiation Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
(4)
Department of Radiology, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Naka Ward, Hamamatsu Shizuoka, 430-8558, Japan
(5)
Department of Radiation Oncology, Faculty of Medicine, Kindai University, 377-2 Ohno-higashi, Osakasayama, Osaka 589-8511, Japan
(6)
Department of Medical Physics, Graduate School of Medical Sciences, Kindai University, 377-2 Ohno-higashi, Osakasayama, Osaka 589-8511, Japan

References

  1. Williams MJ, Bailey MJ, Forstner D, Metcalfe PE. Multicentre quality assurance of intensity-modulated radiation therapy plans: a precursor to clinical trials. Australas Radiol. 2007;51(5):472–9.View ArticlePubMedGoogle Scholar
  2. Chung HT, Lee B, Park E, Lu JJ, Xia P. Can all centers plan intensity-modulated radiotherapy (IMRT) effectively? An external audit of dosimetric comparisons between three-dimensional conformal radiotherapy and IMRT for adjuvant chemoradiation for gastric cancer. Int J Radiat Oncol Biol Phys. 2008;71(4):1167–74.View ArticlePubMedGoogle Scholar
  3. Bohsung J, Gillis S, Arrans R, Bakai A, De Wagter C, Knöös T, Mijnheer BJ, et al. IMRT treatment planning—a comparative inter-system and inter-Centre planning exercise of the QUASIMODO group. Radiother Oncol. 2005;76:354–61.View ArticlePubMedGoogle Scholar
  4. Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, et al. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol. 2015;33(2):156–64.View ArticlePubMedGoogle Scholar
  5. Moore KL, Schmidt R, Moiseenko V, Olsen LA, Tan J, Xiao Y, et al. Quantifying unnecessary normal tissue complication risks due to suboptimal planning: a secondary study of RTOG 0126. Int J Radiat Oncol Biol Phys. 2015;92:228–35.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Wu B, McNutt T, Zahurak M, Simari P, Pang D, Taylor R, et al. Fully automated simultaneous integrated boosted-intensity modulated radiation therapy treatment planning is feasible for head-and-neck cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys. 2012;84:e647–53.View ArticlePubMedGoogle Scholar
  7. Tol JP, Dahele M, Delaney AR, Slotman BJ, Verbakel WF. Can knowledge-based DVH predictions be used for automated, individualized quality assurance of radiotherapy treatment plans? Radiat Oncol. 2015;10:234.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Yuan L, Ge Y, Lee WR, Yin FF, Kirkpatrick JP, Wu QJ. Quantitative analysis of the factors which affect the interpatient organ-at-risk dose sparing variation in IMRT plans. Med Phys. 2012;39(11):6868–78.View ArticlePubMedGoogle Scholar
  9. Tol JP, Delaney AR, Dahele M, Slotman BJ, Verbakel WF. Evaluation of a knowledge-based planning solution for head and neck cancer. Int J Radiat Oncol Biol Phys. 2015;91(3):612–20.View ArticlePubMedGoogle Scholar
  10. Fogliata A, Nicolini G, Clivio A, Vanetti E, Laksar S, Tozzi A, et al. A broad scope knowledge based model for optimization of VMAT in esophageal cancer: validation and assessment of plan quality among different treatment centers. Radiat Oncol. 2015;10(1):220.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Wu H, Jiang F, Yue H, Li S, Zhang Y. A dosimetric evaluation of knowledgebased VMAT planning with simultaneous integrated boosting for rectal cancer patients. J Appl Clin Med Phys. 2016;17(6):78–85.View ArticlePubMedGoogle Scholar
  12. Kubo K, Monzen H, Ishii K, Tamura M, Kawamorita R, Sumida I, et al. Dosimetric comparison of RapidPlan and manually optimized plans in volumetric modulated arc therapy for prostate cancer. Phys Med. 2017;S1120-1790(17):30216–8.Google Scholar
  13. Schubert C, Waletzko O, Weiss C, Voelzke D, Toperim S, Roeser A, et al. Intercenter validation of a knowledge based model for automated planning of volumetric modulated arc therapy for prostate cancer. The experience of the German RapidPlan consortium. PLoS One. 2017;12(5):e0178034.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Peeters ST, Lebesque JV, Heemsbergen WD, van Putten WL, Slot A, Dielwart MF, et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2006;64:1151–61.View ArticlePubMedGoogle Scholar
  15. Harsolia A, Vargas C, Yan D, Brabbins D, Lockman D, Liang J, et al. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II doseescalation study. Int J Radiat Oncol Biol Phys. 2007;69:1100–9.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2018

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement